Show simple item record

dc.contributor.authorPalm, Kaia et al.
dc.description.abstractLittle is known about the quality of polyclonal antibody responses in COVID-19 patients, and how it correlates with disease severity or patients' prior exposure to other pathogens. The whole polyclonal antibody repertoire in a retrospective cohort of 538 individuals was mapped against SARS-CoV-2 spike (S) glycoprotein, the main target of antibody immune responses in SARS-CoV-2 infection. Bioinformatic predictions identified 15 major B cell epitopes for S of SARS-CoV-2. Several epitopes localised in RBD of S including those spanning the ACE2-binding site, the highly conserved cryptic epitope of the neutralizing antibody of SARS-CoV, and fusion/entry domains of HR1 and HR2 of S protein of SARS-CoV-2. Intriguingly, some of these epitopes have cross-reactivity to antigens of common pathogens, potentially affecting SARS-CoV-2 infection outcome. High level of anti-Spike SARS-CoV-2 seroreactivity in populations with no history of exposure to SARS-CoV-2 is of clinical relevance and could underpin better understanding of COVID-19 pathophysiology in different populations and provide a blueprint for design of effective vaccines and developing better strategies for antibody testing.en_US
dc.subjectCohort Studiesen_US
dc.subjectCoronavirus Infectionsen_US
dc.titleHigh seroreactivity against SARS-CoV-2 Spike epitopes in a pre SARS-CoV-2 cohort: implications for antibody testing and vaccine designen_US
eihealth.countryGlobal (WHO/OMS)en_US
eihealth.categoryVirus: natural history, transmission and diagnosticsen_US
eihealth.typePublished Articleen_US
eihealth.maincategorySlow Spread / Reducir la Dispersiónen_US

Files in this item


There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record